Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation

J. R. Passweg; H. Baldomero; C. Peters; H. B. Gaspar; S. Cesaro; P. Dreger; R. F. Duarte; J. H. F. Falkenburg; D. Farge-Bancel; A. Gennery; J. Halter; N. Kroeger; F. Lanza; J. Marsh; M. Mohty; A. Sureda; A. Velardi; A. Madrigal; European Soc Blood Marrow Transpla

doi:10.1038/bmt.2014.55

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation

J. R. Passweg^*, H. Baldomero, C. Peters, H. B. Gaspar, S. Cesaro, P. Dreger, R. F. Duarte, J. H. F. Falkenburg, D. Farge-Bancel, A. Gennery, J. Halter, N. Kroeger, F. Lanza, J. Marsh, M. Mohty, A. Sureda, A. Velardi, A. Madrigal, European Soc Blood Marrow Transpla

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

151 Citations (Scopus)

Abstract

In all, 661 of 680 centers in 48 countries reported 37 818 hematopoietic SCT ( HSCT) in 33 678 patients (14 165 allogeneic (42%), 19 513 autologous (58%)) in the 2012 survey. Main indications were leukemias, 10 641 (32%; 95% allogeneic); lymphoid neoplasias, 19 336 (57%; 11% allogeneic); solid tumors, 1630 (5%; 3% allogeneic); and nonmalignant disorders, 1953 (6%; 90% allogeneic). There were more unrelated donors than HLA-identical sibling donors (54% versus 38% (8% being mismatched related donor HSCT)). Cord blood was almost exclusive in allogeneic transplants ( 5% of total). Since 2011, the highest increases in allogeneic HSCT were for AML in CR1 (12%) and for myeloproliferative neoplasm (15%). For autologous HSCT the main increases were for plasma cell disorders (7%), non-Hodgkin lymphoma (4%) and autoimmune disease (50%). There were 4097 pediatric patients <18 years of age receiving HSCT, 2902 received an allogeneic and 1195 an autologous HSCT. Overall, 69% of allogeneic and 64% of autologous HSCT were performed in dedicated pediatric centers and the remainder in combined adult and pediatric centers. Distributions of diseases, donor types and stem cell source for all patients and pediatric patients in particular are shown. A percentage of centers fulfilling the annual required criteria for patient numbers for JACIE accreditation are provided.

Original language	English
Pages (from-to)	744-750
Number of pages	7
Journal	Bone Marrow Transplantation
Volume	49
Issue number	6
DOIs	https://doi.org/10.1038/bmt.2014.55
Publication status	Published - Jun 2014

Keywords

STEM-CELL TRANSPLANTATION

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bmt.2014.55

Cite this

Passweg, J. R., Baldomero, H., Peters, C., Gaspar, H. B., Cesaro, S., Dreger, P., Duarte, R. F., Falkenburg, J. H. F., Farge-Bancel, D., Gennery, A., Halter, J., Kroeger, N., Lanza, F., Marsh, J., Mohty, M., Sureda, A., Velardi, A., Madrigal, A., & European Soc Blood Marrow Transpla (2014). Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplantation, 49(6), 744-750. https://doi.org/10.1038/bmt.2014.55

@article{f55d51c0ec85438ba9264646fc99e857,

title = "Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation",

abstract = "In all, 661 of 680 centers in 48 countries reported 37 818 hematopoietic SCT ( HSCT) in 33 678 patients (14 165 allogeneic (42%), 19 513 autologous (58%)) in the 2012 survey. Main indications were leukemias, 10 641 (32%; 95% allogeneic); lymphoid neoplasias, 19 336 (57%; 11% allogeneic); solid tumors, 1630 (5%; 3% allogeneic); and nonmalignant disorders, 1953 (6%; 90% allogeneic). There were more unrelated donors than HLA-identical sibling donors (54% versus 38% (8% being mismatched related donor HSCT)). Cord blood was almost exclusive in allogeneic transplants ( 5% of total). Since 2011, the highest increases in allogeneic HSCT were for AML in CR1 (12%) and for myeloproliferative neoplasm (15%). For autologous HSCT the main increases were for plasma cell disorders (7%), non-Hodgkin lymphoma (4%) and autoimmune disease (50%). There were 4097 pediatric patients <18 years of age receiving HSCT, 2902 received an allogeneic and 1195 an autologous HSCT. Overall, 69% of allogeneic and 64% of autologous HSCT were performed in dedicated pediatric centers and the remainder in combined adult and pediatric centers. Distributions of diseases, donor types and stem cell source for all patients and pediatric patients in particular are shown. A percentage of centers fulfilling the annual required criteria for patient numbers for JACIE accreditation are provided.",

keywords = "STEM-CELL TRANSPLANTATION",

author = "Passweg, {J. R.} and H. Baldomero and C. Peters and Gaspar, {H. B.} and S. Cesaro and P. Dreger and Duarte, {R. F.} and Falkenburg, {J. H. F.} and D. Farge-Bancel and A. Gennery and J. Halter and N. Kroeger and F. Lanza and J. Marsh and M. Mohty and A. Sureda and A. Velardi and A. Madrigal and {European Soc Blood Marrow Transpla}",

year = "2014",

month = jun,

doi = "10.1038/bmt.2014.55",

language = "English",

volume = "49",

pages = "744--750",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "6",

}

Passweg, JR, Baldomero, H, Peters, C, Gaspar, HB, Cesaro, S, Dreger, P, Duarte, RF, Falkenburg, JHF, Farge-Bancel, D, Gennery, A, Halter, J, Kroeger, N, Lanza, F, Marsh, J, Mohty, M, Sureda, A, Velardi, A, Madrigal, A & European Soc Blood Marrow Transpla 2014, 'Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation', Bone Marrow Transplantation, vol. 49, no. 6, pp. 744-750. https://doi.org/10.1038/bmt.2014.55

TY - JOUR

T1 - Hematopoietic SCT in Europe

T2 - data and trends in 2012 with special consideration of pediatric transplantation

AU - Passweg, J. R.

AU - Baldomero, H.

AU - Peters, C.

AU - Gaspar, H. B.

AU - Cesaro, S.

AU - Dreger, P.

AU - Duarte, R. F.

AU - Falkenburg, J. H. F.

AU - Farge-Bancel, D.

AU - Gennery, A.

AU - Halter, J.

AU - Kroeger, N.

AU - Lanza, F.

AU - Marsh, J.

AU - Mohty, M.

AU - Sureda, A.

AU - Velardi, A.

AU - Madrigal, A.

AU - European Soc Blood Marrow Transpla

PY - 2014/6

Y1 - 2014/6

N2 - In all, 661 of 680 centers in 48 countries reported 37 818 hematopoietic SCT ( HSCT) in 33 678 patients (14 165 allogeneic (42%), 19 513 autologous (58%)) in the 2012 survey. Main indications were leukemias, 10 641 (32%; 95% allogeneic); lymphoid neoplasias, 19 336 (57%; 11% allogeneic); solid tumors, 1630 (5%; 3% allogeneic); and nonmalignant disorders, 1953 (6%; 90% allogeneic). There were more unrelated donors than HLA-identical sibling donors (54% versus 38% (8% being mismatched related donor HSCT)). Cord blood was almost exclusive in allogeneic transplants ( 5% of total). Since 2011, the highest increases in allogeneic HSCT were for AML in CR1 (12%) and for myeloproliferative neoplasm (15%). For autologous HSCT the main increases were for plasma cell disorders (7%), non-Hodgkin lymphoma (4%) and autoimmune disease (50%). There were 4097 pediatric patients <18 years of age receiving HSCT, 2902 received an allogeneic and 1195 an autologous HSCT. Overall, 69% of allogeneic and 64% of autologous HSCT were performed in dedicated pediatric centers and the remainder in combined adult and pediatric centers. Distributions of diseases, donor types and stem cell source for all patients and pediatric patients in particular are shown. A percentage of centers fulfilling the annual required criteria for patient numbers for JACIE accreditation are provided.

AB - In all, 661 of 680 centers in 48 countries reported 37 818 hematopoietic SCT ( HSCT) in 33 678 patients (14 165 allogeneic (42%), 19 513 autologous (58%)) in the 2012 survey. Main indications were leukemias, 10 641 (32%; 95% allogeneic); lymphoid neoplasias, 19 336 (57%; 11% allogeneic); solid tumors, 1630 (5%; 3% allogeneic); and nonmalignant disorders, 1953 (6%; 90% allogeneic). There were more unrelated donors than HLA-identical sibling donors (54% versus 38% (8% being mismatched related donor HSCT)). Cord blood was almost exclusive in allogeneic transplants ( 5% of total). Since 2011, the highest increases in allogeneic HSCT were for AML in CR1 (12%) and for myeloproliferative neoplasm (15%). For autologous HSCT the main increases were for plasma cell disorders (7%), non-Hodgkin lymphoma (4%) and autoimmune disease (50%). There were 4097 pediatric patients <18 years of age receiving HSCT, 2902 received an allogeneic and 1195 an autologous HSCT. Overall, 69% of allogeneic and 64% of autologous HSCT were performed in dedicated pediatric centers and the remainder in combined adult and pediatric centers. Distributions of diseases, donor types and stem cell source for all patients and pediatric patients in particular are shown. A percentage of centers fulfilling the annual required criteria for patient numbers for JACIE accreditation are provided.

KW - STEM-CELL TRANSPLANTATION

U2 - 10.1038/bmt.2014.55

DO - 10.1038/bmt.2014.55

M3 - Article

SN - 0268-3369

VL - 49

SP - 744

EP - 750

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 6

ER -

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this